Cardiovascular Prevention for Persons With HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00982189
Recruitment Status : Completed
First Posted : September 23, 2009
Results First Posted : April 18, 2012
Last Update Posted : November 22, 2017
American Heart Association
Information provided by (Responsible Party):
Minneapolis Medical Research Foundation

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Factorial Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Prevention
Conditions: HIV Infection
Cardiovascular Disease Risk
Interventions: Drug: Pravastatin
Drug: Lisinopril

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Lisinopril/P-placebo Lisinopril 10mg and placebo (matched to pravastatin) once daily
L-placebo/Pravastatin Placebo pill (matched to lisinopril) and Pravastatin 20mg once daily
Lisinopril/Pravastatin Lisinopril 10mg and Pravastatin 20mg once daily
L-placebo/P-placebo Placebo pill (matched to pravastatin) and placebo pill (matched to lisinopril) once daily

Participant Flow:   Overall Study
    Lisinopril/P-placebo   L-placebo/Pravastatin   Lisinopril/Pravastatin   L-placebo/P-placebo
STARTED   10   9   9   9 
COMPLETED   10   9   9   9 
NOT COMPLETED   0   0   0   0 

  Baseline Characteristics

  Outcome Measures

1.  Primary:   Number of Participants Who Stated (by Self-report) That They Had Side Effects   [ Time Frame: 4 months ]

2.  Primary:   Number of Participants Who Took >90% of Their Doses (by Pill Count)   [ Time Frame: 4 months ]

3.  Primary:   Change From Baseline to Month 4 in the Framingham Risk Score (FRS)   [ Time Frame: Change from baseline to 4 months ]

4.  Secondary:   Changes in Blood Pressure   [ Time Frame: change from baseline to 4 months ]

5.  Secondary:   Changes in Blood Lipids   [ Time Frame: change from baseline to 4 months ]

6.  Secondary:   Changes in Small Artery Elasticity   [ Time Frame: change from baseline to 4 months ]

7.  Secondary:   Changes hsCRP (C-reactive Protein)   [ Time Frame: change from baseline to 4 months ]

8.  Secondary:   Changes IL-6 (Interleukin-6)   [ Time Frame: change from baseline to 4 months ]

9.  Secondary:   Changes TNFa (Tumor Necrosis Factor Alpha)   [ Time Frame: change from baseline to 4 months ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Study was small with limited power to detect differences.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Dr. Jason Baker
Organization: Minneapolis Medical Foundation
phone: 612-873-2705

Publications automatically indexed to this study by Identifier (NCT Number):

Responsible Party: Minneapolis Medical Research Foundation Identifier: NCT00982189     History of Changes
Other Study ID Numbers: PCC-003
First Submitted: September 22, 2009
First Posted: September 23, 2009
Results First Submitted: January 16, 2012
Results First Posted: April 18, 2012
Last Update Posted: November 22, 2017